Health X Platform Limited has formally announced an analyst and investor meeting scheduled for March 19, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company, formerly known as sastasundar ventures Limited, communicated this development to both BSE Limited and National Stock Exchange of India Limited on March 16, 2026.

Meeting Details and Format

The analyst meeting will be conducted as an in-person group conference at Godrej BKC, Mumbai. The session is structured to accommodate investors and analysts through two one-hour slots within the designated timeframe.

Regulatory Compliance and Information Sharing

The company has emphasized strict adherence to regulatory guidelines during the investor interaction. Health X Platform Limited has explicitly stated that only information available in the public domain will be shared and discussed during the meeting. The company has committed to ensuring no unpublished price sensitive information will be disclosed during the analyst and investor interactions.

Communication and Accessibility

The meeting schedule has been communicated to relevant stock exchanges as required under Regulation 30 of SEBI Listing Regulations. The company has noted that the schedule may be subject to change due to exigencies on the part of analysts or investors. Additionally, the communication will be made available on multiple platforms including the company's website, BSE Limited's portal, and National Stock Exchange of India Limited's website for broader accessibility and transparency.

The announcement was signed by Pratap Singh, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols are followed for this investor engagement initiative.

Health X Platform Limited (formerly Sastasundar Ventures Limited) has received board approval for executing a tripartite agreement with its material subsidiary Sastasundar Healthbuddy Limited (SHBL) and Envision India Fund. The board of directors approved the agreement execution under Regulation 30A of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Agreement Framework and Parties

The tripartite agreement involves Health X Platform Limited, SHBL, and Envision India Fund, a qualified institutional buyer registered in Mauritius with registration number GB20025232. The agreement follows the share purchase agreement dated February 25, 2026, where Envision acquired Mitsubishi Corporation's entire shareholding in SHBL comprising 10.14 lakh equity shares valued at Rs. 50.00 crore at Rs. 493.21 per share.

Merger and Share Swap Provisions

The tripartite agreement contemplates a scheme of arrangement between Health X Platform and SHBL, whereby SHBL shall be merged with Health X Platform subject to compliance with applicable laws. The merger structure ensures Envision's economic interest in Health X Platform post-merger remains equivalent to its pre-merger stake in SHBL.

If the scheme of arrangement resulting in merger cannot be consummated, Health X Platform will undertake a share swap arrangement to provide Envision equivalent shares in lieu of SHBL holdings. The company previously disclosed in-principle approval for the merger scheme on February 26, 2026.

Post-Transaction Shareholding Structure

Following the completion of the transaction, SHBL's shareholding structure comprises Health X Platform Limited holding 17,100,160 equity shares, Rohto Pharmaceuticals Co., Ltd. with 3,562,064 equity shares, and Envision India Fund with 10,13,766 equity shares, totaling 21,675,990 equity shares.

Governance Rights and Board Representation

The tripartite agreement grants Envision India Fund the right to nominate one director on Health X Platform's board in case of material breach or non-consummation of the merger. This provision ensures Envision maintains governance participation aligned with its investment stake and strategic interests in the healthcare platform.

Regulatory Compliance and Disclosure

Company Secretary and Compliance Officer Pratap Singh executed the regulatory disclosure under SEBI guidelines, maintaining transparency with stock exchanges. The transaction falls within related party transaction scope as SHBL is a material subsidiary of Health X Platform, with the company being SHBL's promoter.